Dr. Crown on the Investigation of Lapatinib Plus Chemotherapy in HER2+ Breast Cancer
February 3rd 2023
John Crown, MB, BCh, BAO, BSc, MD, MBA, discusses the rationale for evaluating lapatinib (Tykerb) with standard trastuzumab/chemotherapy regimen in patients with HER2-positive breast cancer, as well as contextualizes results from a phase 2 trial.